Cargando…
Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study
BACKGROUND: On Dec 8, 2020, deployment of the first SARS-CoV-2 vaccination authorised for UK use (BNT162b2 mRNA vaccine) began, followed by an adenoviral vector vaccine ChAdOx1 nCoV-19 on Jan 4, 2021. Care home residents and staff, frontline health-care workers, and adults aged 80 years and older we...
Autores principales: | Hyams, Catherine, Marlow, Robin, Maseko, Zandile, King, Jade, Ward, Lana, Fox, Kazminder, Heath, Robyn, Tuner, Anabella, Friedrich, Zsolt, Morrison, Leigh, Ruffino, Gabriella, Antico, Rupert, Adegbite, David, Szasz-Benczur, Zsuzsa, Garcia Gonzalez, Maria, Oliver, Jennifer, Danon, Leon, Finn, Adam |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8221734/ https://www.ncbi.nlm.nih.gov/pubmed/34174190 http://dx.doi.org/10.1016/S1473-3099(21)00330-3 |
Ejemplares similares
-
Heterologous prime–boost vaccination with ChAdOx1 nCoV-19 and BNT162b2
por: Tenbusch, Matthias, et al.
Publicado: (2021) -
Evaluation of Cellular Responses to ChAdOx1-nCoV-19 and BNT162b2 Vaccinations
por: Lee, Tae Hwan, et al.
Publicado: (2023) -
Postvaccinal Encephalitis after ChAdOx1 nCov‐19
por: Zuhorn, Frédéric, et al.
Publicado: (2021) -
BNT162b2 COVID-19 and ChAdOx1 nCoV-19 vaccination in patients with myelodysplastic syndromes
por: Abdul-Jawad, Sultan, et al.
Publicado: (2022) -
Comparative effectiveness of BNT162b2 and ChAdOx1 nCoV-19 vaccines against COVID-19
por: Wei, Jie, et al.
Publicado: (2023)